Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Capricor Therapeutics
(NASDAQ:CAPR)
Intraday
$5.48
0.15
[2.81%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$5.48
0.15
[2.81%]
Last update: 7:18AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Capricor Therapeutics Stock (NASDAQ:CAPR)
Capricor Therapeutics Stock (NASDAQ: CAPR)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 25, 2024
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Benzinga Newsdesk
-
5 days ago
Wednesday, April 24, 2024
Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting
Benzinga Newsdesk
-
6 days ago
Friday, March 01, 2024
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Benzinga Newsdesk
-
Mar 1, 2024, 6:51AM
Thursday, February 29, 2024
Recap: Capricor Therapeutics Q4 Earnings
Benzinga Insights
-
Feb 29, 2024, 4:30PM
Capricor Therapeutics Q4 2023 GAAP EPS $(0.020) Beats $(0.200) Estimate, Sales $12.088M Beat $10.600M Estimate
Benzinga Newsdesk
-
Feb 29, 2024, 4:27PM
Earnings Scheduled For February 29, 2024
Benzinga Insights
-
Feb 29, 2024, 5:15AM
Wednesday, February 28, 2024
Capricor Therapeutics's Earnings Outlook
Benzinga Insights
-
Feb 28, 2024, 12:01PM
Tuesday, February 27, 2024
Capricor Therapeutics Announces Type-B Meeting With FDA For Commercial Manufacturing Planning To Expedite BLA Pathway For CAP-1002 In Duchenne Muscular Dystrophy
Benzinga Newsdesk
-
Feb 27, 2024, 8:32AM
Tuesday, February 20, 2024
Capricor Therapeutics Announces Manufacturing Scale-Up Of CAP-1002 Production At New San Diego Facility
Benzinga Newsdesk
-
Feb 20, 2024, 8:34AM
Wednesday, January 24, 2024
Capricor Therapeutics Collabores With National Institutes Of Health For Clinical Trial Of Exosome-Based Multivalent Vaccine For SARS-CoV-2
Benzinga Newsdesk
-
Jan 24, 2024, 9:16AM
Thursday, January 11, 2024
Capricor Therapeutics Receives First Milestone Payment Of $10M From Nippon Shinyaku, Co. Under Exclusive Commercialization And Distribution Agreement
Benzinga Newsdesk
-
Jan 11, 2024, 9:07AM
Friday, January 05, 2024
Cantor Fitzgerald Initiates Coverage On Capricor Therapeutics with Overweight Rating, Announces Price Target of $8
Benzinga Newsdesk
-
Jan 5, 2024, 10:31AM
Monday, December 11, 2023
Capricor Therapeutics Announces Outcome Of Phase 3 HOPE-3 Trial Of CAP-1002 In Duchenne Muscular Dystrophy Based On Completion Of Interim Futility Analysis; Results In Recommendation To Continue Trial
Benzinga Newsdesk
-
Dec 11, 2023, 9:06AM
Tuesday, November 14, 2023
Capricor Says Its Available Cash & Equivalents Will Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into 2025
Benzinga Newsdesk
-
Nov 14, 2023, 4:41PM
Capricor Therapeutics Q3 EPS $(0.25) Vs $(0.26) Last Year, Sales $6.18M Beat $2.11M Estimate
Benzinga Newsdesk
-
Nov 14, 2023, 4:11PM
Earnings Scheduled For November 14, 2023
Benzinga Insights
-
Nov 14, 2023, 8:23AM
Monday, November 13, 2023
Preview: Capricor Therapeutics's Earnings
Benzinga Insights
-
Nov 13, 2023, 9:01AM
Wednesday, October 25, 2023
Chief Financial Officer at Capricor Therapeutics Exercises Options Worth $6K
Benzinga Insights
-
Oct 25, 2023, 11:00AM
Tuesday, October 24, 2023
Capricor Therapeutics Chief Financial Officer Acquires 2,178 Shares After Exercising Company Stock Options
Benzinga Insights
-
Oct 24, 2023, 11:00AM
Thursday, October 19, 2023
Capricor Therapeutics And Parent Project Muscular Dystrophy To Host Webinar To Review Latest Developments Of CAP-1002 Program
Benzinga Newsdesk
-
Oct 19, 2023, 4:03PM
Thursday, October 12, 2023
FlexShopper And 3 Other Penny Stocks Insiders Are Buying
Lisa Levin
-
Oct 12, 2023, 8:42AM
Tuesday, October 10, 2023
Capricor Therapeutics Announces Late-Breaking Presentations At 28th Annual Congress Of tThe World Muscle Society
Benzinga Newsdesk
-
Oct 10, 2023, 9:16AM
Monday, October 09, 2023
Cadrenal Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying
Lisa Levin
-
Oct 9, 2023, 8:51AM
Wednesday, October 04, 2023
HC Wainwright & Co. Maintains Buy on Capricor Therapeutics, Raises Price Target to $40
Benzinga Newsdesk
-
Oct 4, 2023, 6:14AM
Tuesday, October 03, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Oct 3, 2023, 2:37PM
Monday, October 02, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Oct 2, 2023, 1:00PM
Friday, September 29, 2023
US Stocks Turn Lower; Dow Tumbles Over 200 Points
Lisa Levin
-
Sep 29, 2023, 2:33PM
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Sep 29, 2023, 2:09PM
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Sep 29, 2023, 1:31PM
Crude Oil Down 1% Following PCE Data; Blue Apron Shares Surge
Lisa Levin
-
Sep 29, 2023, 12:05PM
Nasdaq Gains Over 1%; Nike Posts Upbeat Earnings
Lisa Levin
-
Sep 29, 2023, 10:16AM
Capricor Therapeutics shares are trading lower after the company announced a $23 million registered direct offering.
Benzinga Newsdesk
-
Sep 29, 2023, 9:14AM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Sep 29, 2023, 9:05AM
Capricor Therapeutics Announced A Registered Direct Offering Of 4.9M Shares, Each Share Was Sold With A Warrant To Purchase One Share At A Combined Price Of $4.66, With Gross Proceeds Of $23M
Benzinga Newsdesk
-
Sep 29, 2023, 7:40AM
Capricor Therapeutics Announced An Update On Its Type-b Clinical Meeting With The FDA On The Design And Execution Of The HOPE-3 Phase 3 Trial With Lead Asset CAP-1002 For Duchenne Muscular Dystrophy
Benzinga Newsdesk
-
Sep 29, 2023, 7:35AM
Tuesday, August 29, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Aug 29, 2023, 1:31PM
Wednesday, August 23, 2023
Top 5 Health Care Stocks That May Fall Off A Cliff
Lisa Levin
-
Aug 23, 2023, 7:58AM
Tuesday, August 15, 2023
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $18 Price Target
Benzinga Newsdesk
-
Aug 15, 2023, 6:39AM
Monday, August 07, 2023
Capricor Therapeutics Q2 EPS $(0.29) Beats $(0.35) Estimate, Sales $3.92M Beat $1.50M Estimate
Benzinga Newsdesk
-
Aug 7, 2023, 4:34PM
Earnings Scheduled For August 7, 2023
Benzinga Insights
-
Aug 7, 2023, 4:12AM
Friday, June 30, 2023
Capricor Therapeutics Announces 24-Month Results From Ongoing HOPE-2 Open Label Extension Study Of CAP-1002 In Duchenne Muscular Dystrophy
Benzinga Newsdesk
-
Jun 30, 2023, 9:28AM
Tuesday, June 13, 2023
Capricor Therapeutics To Present 24-Month Results From Ongoing HOPE-2 Open Label Extension Study Of CAP-1002 In Duchenne Muscular Dystrophy
Benzinga Newsdesk
-
Jun 13, 2023, 9:17AM
Wednesday, June 07, 2023
Capricor Therapeutics Announces Follow-Up Type-B Clinical Meeting With The FDA For CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy
Benzinga Newsdesk
-
Jun 7, 2023, 9:17AM
Wednesday, May 17, 2023
Capricor Therapeutics Chief Executive Officer Acquires 41,497 Shares After Exercising Company Stock Options
Benzinga Insights
-
May 17, 2023, 11:01AM
Thursday, May 11, 2023
Recap: Capricor Therapeutics Q1 Earnings
Benzinga Insights
-
May 11, 2023, 4:05PM
Capricor Therapeutics Q1 EPS $(0.31) Beats $(0.32) Estimate, Sales $2.99M Beat $500.00K Estimate
Benzinga Newsdesk
-
May 11, 2023, 4:03PM
Earnings Scheduled For May 11, 2023
Benzinga Insights
-
May 11, 2023, 9:58AM
Thursday, April 27, 2023
Capricor Announces Peer-Reviewed Publication Demonstrating The Therapeutic Potential Of Exosome-Based Multivalent Vaccine Developed From Its StealthX Platform
Happy Mohamed
-
Apr 27, 2023, 9:21AM
Thursday, March 16, 2023
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $18 Price Target
Benzinga Newsdesk
-
Mar 16, 2023, 6:17AM
Wednesday, March 15, 2023
Capricor Therapeutics Q4 EPS $(0.31) Beats $(0.33) Estimate
Benzinga Newsdesk
-
Mar 15, 2023, 4:02PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch